Pay in 4 interest-free payments of $5.91 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
On May 13, at the 33rd European Congress on Obesity in Istanbul, Trkiye, findings from the Phase III SURMOUNT-MAINTAIN trial (NCT06047548) were presented, evaluating the use of Eli Lilly's Zepbound (tirzepatide) in sustaining weight loss following an initial 60-week open-label weight-loss period
Novo Nordisk throttled distribution of smaller Wegovy doses in the U.S
Loading the skeleton is the intervention with the best evidence behind it, and if you are in your forties or fifties this is not a distant concern
Some patients start with brand-name at the $199 introductory price for the first two months, then switch to compounded at $199 ongoing to maintain the lowest cost
As evidence accumulates on the broader benefits of GLP-1 therapies, pressure is building to expand reimbursement for obesity indications
The endogenous protein plays crucial roles in cellular differentiation, tissue remodeling, and wound healing processes
